Lyra Therapeutics, Inc.
LYRA
$0.0873
$0.00080.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.53M | 1.47M | 1.82M | 1.68M | 1.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.53M | 1.47M | 1.82M | 1.68M | 1.56M |
| Cost of Revenue | 43.77M | 49.67M | 56.14M | 53.67M | 48.03M |
| Gross Profit | -42.23M | -48.20M | -54.32M | -51.99M | -46.47M |
| SG&A Expenses | 18.50M | 19.25M | 20.32M | 19.75M | 19.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.27M | 68.92M | 76.45M | 73.42M | 67.09M |
| Operating Income | -60.73M | -67.44M | -74.63M | -71.74M | -65.53M |
| Income Before Tax | -93.40M | -97.56M | -101.33M | -68.82M | -62.62M |
| Income Tax Expenses | 39.00K | 50.00K | 59.00K | 59.00K | 59.00K |
| Earnings from Continuing Operations | -93.44 | -97.61 | -101.39 | -68.88 | -62.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.44M | -97.61M | -101.39M | -68.88M | -62.68M |
| EBIT | -60.73M | -67.44M | -74.63M | -71.74M | -65.53M |
| EBITDA | -60.26M | -67.04M | -74.20M | -71.32M | -64.96M |
| EPS Basic | -1.44 | -1.51 | -1.67 | -1.30 | -1.39 |
| Normalized Basic EPS | -0.56 | -0.62 | -0.75 | -0.79 | -0.84 |
| EPS Diluted | -1.44 | -1.51 | -1.67 | -1.30 | -1.39 |
| Normalized Diluted EPS | -0.56 | -0.62 | -0.75 | -0.79 | -0.84 |
| Average Basic Shares Outstanding | 260.44M | 256.46M | 236.90M | 215.12M | 187.94M |
| Average Diluted Shares Outstanding | 260.44M | 256.46M | 236.90M | 215.12M | 187.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |